A phase IIb study of ramucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic, chemotherapy refractory colorectal cancer patients: The RAMTAS trial of the German AIO (KRK-0316).

Stefan Kasper,Gerrit zur Hausen,Alexander Stein,Sebastian Stintzing,Andreas Berger,Sonja Loges,Ralf Hofheinz,Tanja Trarbach,Ullrich Graeven,Ludwig Fischer von Weikersthal,Thorsten Oliver Goetze,Volker A. Hagen,Susen Burock,Albrecht Hoffmeister,Tobias Dechow,Claudia Pauligk,Isabel Virchow,Jens T. Siveke,Salah-Eddin Al-Batran,Martin Schuler

A phase IIb study of ramucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic, chemotherapy refractory colorectal cancer patients: The RAMTAS trial of the German AIO (KRK-0316).

2019

TPS3617Background: Patients with metastatic colorectal cancer (mCRC) with progressive disease on/after or who are intolerant to fluoropyrimidines, oxaliplatin, irinotecan, anti-angiogenic and anti-...

Keywords:

Refractory
Colorectal cancer
Pathology
Internal medicine
Oncology
Ramucirumab
Medicine
Chemotherapy
German
Irinotecan
Oxaliplatin
Progressive disease

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations